Bliss GVS Pharma Limited
NSE: BLISSGVS BSE: BLISSGVS
NSE
219.02
8.44 (4.01%)
Prev Close
210.58
Open Price
212
Volume
1,767,243
Today Low / High
209.62 / 221.8
52 WK Low / High
108.12 / 243.9
Range
208 - 230
BSE
219.05
8.75 (4.16%)
Prev Close
210.3
Open Price
213
Volume
77,474
Today Low / High
209.65 / 221.9
52 WK Low / High
105.05 / 244.05
Range
208 - 230
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 219.02 (target range: 208 - 230), reflecting a change of 8.44 (4.00798%). On the BSE, it is listed at 219.05 (target range: 208 - 230), showing a change of 8.75 (4.16072%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
25 Feb
212.00
3.31%
24 Feb
225.00
-6.41%
23 Feb
225.00
0.03%
20 Feb
225.10
-0.82%
19 Feb
230.70
-1.83%
18 Feb
233.00
-1.28%
17 Feb
222.00
4.14%
16 Feb
215.99
2.77%
13 Feb
218.00
-0.08%
12 Feb
215.00
1.49%
11 Feb
208.00
2.99%
10 Feb
208.00
0.03%
09 Feb
183.50
10.95%
06 Feb
185.00
-0.97%
05 Feb
183.15
1.44%
04 Feb
179.00
2.95%
03 Feb
175.00
3.15%
02 Feb
168.70
2.41%
01 Feb
176.00
-3.13%
30 Jan
181.00
-2.36%
29 Jan
168.00
9.01%
28 Jan
166.83
0.54%
Bliss GVS Pharma Limited Graph
Bliss GVS Pharma Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Bliss GVS Pharma Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 219.02, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 219.05 | 221.24 | 199.12 - 243.36 |
| 223.43 | 178.74 - 268.12 | ||
| 225.62 | 157.94 - 293.31 | ||
| Bearish Scenario | 219.05 | 216.86 | 195.17 - 238.55 |
| 214.67 | 171.74 - 257.60 | ||
| 212.48 | 148.73 - 276.22 |
Overview of Bliss GVS Pharma Limited
ISIN
INE416D01022
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
5,371,498
Market Cap
23,169,900,647
Last Dividend
1
Official Website
IPO Date
2010-07-26
DCF Diff
75.18
DCF
142
Financial Ratios Every Investor Needs
Stock Dividend of BLISSGVS
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2026-02-18 | February 18, 26 | 0.5 | 0.5 | 2026-02-18 | 2026-03-12 | |
| 2025-07-24 | July 24, 25 | 0.5 | 0.5 | 2025-07-24 | 2025-08-30 | |
| 2024-07-18 | July 18, 24 | 0.5 | 0.5 | 2024-07-18 | 2024-08-24 | |
| 2023-07-12 | July 12, 23 | 0.5 | 0.5 | 2023-07-12 | 2023-08-18 | |
| 2022-06-20 | June 20, 22 | 0.5 | 0.5 | 2022-06-21 | 2022-07-28 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 809.73 Cr | 413.69 Cr | 396.04 Cr | 0.4891 | 17.37 Cr | 113.24 Cr | 283.99 Cr | 84.30 Cr | 8.02 | 126.68 Cr | 0.1041 |
| 2024-03-31 | 765.91 Cr | 516.48 Cr | 249.43 Cr | 0.3257 | 15.23 Cr | 8.41 Cr | 123.10 Cr | 75.45 Cr | 7.23 | 148.81 Cr | 0.0985 |
| 2023-03-31 | 747.43 Cr | 401.32 Cr | 350.26 Cr | 0.4686 | 12.56 Cr | 7.28 Cr | 100.73 Cr | 70.86 Cr | 6.83 | 135.11 Cr | 0.0948 |
| 2022-03-31 | 737.93 Cr | 390.98 Cr | 346.95 Cr | 0.4702 | 13.10 Cr | 8.88 Cr | 95.02 Cr | 15.04 Cr | 1.46 | 76.24 Cr | 0.0204 |
| 2021-03-31 | 568.69 Cr | 328.91 Cr | 239.78 Cr | 0.4216 | 10.49 Cr | 6.97 Cr | 83.02 Cr | 68.49 Cr | 6.64 | 126.87 Cr | 0.1204 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 23.79 Cr | 1,300.84 Cr | 208.99 Cr | 1,050.3756 Cr | 88.10 Cr | -125.20 Cr | 125.73 Cr | 417.72 Cr | 0.00 Cr | 0.05 Cr | 31.07 Cr | 171.7170 Cr |
| 2024-03-31 | 23.14 Cr | 1,213.87 Cr | 210.89 Cr | 967.1933 Cr | 99.84 Cr | 76.70 Cr | 118.45 Cr | 369.38 Cr | 6.92 Cr | 0.06 Cr | 8.02 Cr | 159.8210 Cr |
| 2023-03-31 | 24.96 Cr | 1,156.85 Cr | 239.43 Cr | 883.8969 Cr | 101.90 Cr | 76.94 Cr | 103.06 Cr | 372.91 Cr | 42.06 Cr | 0.07 Cr | 57.55 Cr | 193.2590 Cr |
| 2022-03-31 | 21.92 Cr | 1,108.75 Cr | 262.28 Cr | 818.7017 Cr | 109.39 Cr | 87.48 Cr | 123.94 Cr | 294.82 Cr | 9.01 Cr | 0.09 Cr | 4.36 Cr | 233.0862 Cr |
| 2021-03-31 | 12.63 Cr | 1,076.79 Cr | 248.88 Cr | 808.2534 Cr | 121.90 Cr | 109.26 Cr | 98.93 Cr | 227.82 Cr | 41.79 Cr | 0.10 Cr | 64.81 Cr | 203.6358 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 105.9129 Cr | -75.4409 Cr | -30.3446 Cr | 29.8476 Cr | 0.2261 Cr | 23.8167 Cr | -76.0653 Cr | 84.2993 Cr | -16.4736 Cr | -5.4487 Cr | -30.4542 Cr |
| 2024-03-31 | 152.4486 Cr | -132.8218 Cr | -20.8930 Cr | 124.1193 Cr | -1.4163 Cr | 23.5906 Cr | -28.3293 Cr | 75.4541 Cr | -8.8958 Cr | -5.3949 Cr | -22.4218 Cr |
| 2023-03-31 | 34.3135 Cr | -7.7509 Cr | -24.9385 Cr | -59.4855 Cr | 3.0198 Cr | 25.0069 Cr | -93.7990 Cr | 106.0716 Cr | -13.8732 Cr | -5.4372 Cr | 15.0032 Cr |
| 2022-03-31 | 135.4806 Cr | -92.9751 Cr | -23.7301 Cr | 61.4775 Cr | 8.8526 Cr | 21.9871 Cr | -74.0031 Cr | 127.7598 Cr | -15.6057 Cr | -5.3265 Cr | -29.0968 Cr |
| 2021-03-31 | 63.9694 Cr | -46.9910 Cr | -20.7980 Cr | 54.8452 Cr | -2.2050 Cr | 13.1345 Cr | -9.1242 Cr | 104.1270 Cr | -8.9288 Cr | -5.5495 Cr | -26.8011 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 218.25 Cr | 101.66 Cr | 116.59 Cr | 0.5342 | 26.44 Cr | 23.27 Cr | 2.20 | 50.73 Cr | 0.1066 |
| 2025-09-30 | 244.40 Cr | 159.67 Cr | 84.73 Cr | 0.3467 | 23.50 Cr | 27.25 Cr | 2.58 | 51.94 Cr | 0.1115 |
| 2025-06-30 | 207.47 Cr | 91.89 Cr | 115.58 Cr | 0.5571 | 33.13 Cr | 43.04 Cr | 4.08 | 76.78 Cr | 0.2074 |
| 2025-03-31 | 197.99 Cr | 99.43 Cr | 98.56 Cr | 0.4978 | 13.05 Cr | 15.54 Cr | 1.47 | 33.15 Cr | 0.0785 |
| 2024-12-31 | 210.42 Cr | 114.20 Cr | 96.22 Cr | 0.4573 | 22.24 Cr | 23.80 Cr | 2.27 | 45.05 Cr | 0.1131 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 195.62 Cr | 5.01 Cr | 200.63 Cr | 491.11 Cr | 119.00 Cr | 890.11 Cr | 422.82 Cr | 1,400.10 Cr | 231.88 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 141.34 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,091.85 Cr |
| 2025-03-31 | 23.79 Cr | 117.57 Cr | 141.37 Cr | 447.28 Cr | 125.73 Cr | 826.51 Cr | 417.72 Cr | 1,300.84 Cr | 208.99 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 219.84 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,048.04 Cr |
| 2024-09-30 | 33.11 Cr | 199.92 Cr | 233.03 Cr | 428.37 Cr | 131.41 Cr | 851.41 Cr | 379.18 Cr | 1,282.51 Cr | 234.46 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 43.04 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 15.54 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 23.80 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 24.26 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 20.70 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,764.20 | ₹4,232,906,754,074.00 | ₹1,200,910.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,395.50 | ₹1,697,804,303,390.00 | ₹348,437.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,418.90 | ₹1,495,556,554,816.00 | ₹359,909.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,306.50 | ₹1,087,750,340,235.00 | ₹2,296,180.00 |
| Lupin Limited | LUPIN | ₹2,292.20 | ₹1,047,633,964,600.00 | ₹1,104,211.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹919.65 | ₹925,383,088,904.00 | ₹564,412.00 |
| Mankind Pharma Limited | MANKIND | ₹2,155.70 | ₹889,883,893,710.00 | ₹802,349.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,211.50 | ₹703,641,166,265.00 | ₹3,039,172.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,625.00 | ₹672,553,125,000.00 | ₹231,439.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,085.00 | ₹588,388,686,765.00 | ₹455,450.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,076.35 | ₹581,074,632,036.00 | ₹2,096,370.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,524.50 | ₹386,772,080,341.00 | ₹102,371.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹3,021.30 | ₹377,468,000,791.00 | ₹185,671.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,085.90 | ₹334,844,408,201.00 | ₹172,351.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,430.80 | ₹271,240,390,232.00 | ₹90,076.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,377.10 | ₹223,767,965,930.00 | ₹212,770.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,869.00 | ₹221,725,000,000.00 | ₹2,566.00 |
| Eris Lifesciences Limited | ERIS | ₹1,380.20 | ₹188,006,552,958.00 | ₹30,161.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹978.20 | ₹175,205,274,834.00 | ₹5,721,405.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,331.00 | ₹171,035,250,259.00 | ₹27,190.00 |
| Granules India Limited | GRANULES | ₹599.95 | ₹145,589,096,164.00 | ₹775,187.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹739.90 | ₹145,437,055,448.00 | ₹143,343.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹897.35 | ₹142,113,093,368.00 | ₹305,229.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,727.00 | ₹131,272,198,992.00 | ₹21,410.00 |
| Cohance Lifesciences Limited | COHANCE | ₹310.50 | ₹118,787,096,970.00 | ₹467,931.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹907.55 | ₹111,389,056,800.00 | ₹41,715.00 |
| Viyash Scientific Limited | VIYASH | ₹219.27 | ₹95,646,792,922.00 | ₹684,479.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,136.00 | ₹85,254,425,952.00 | ₹7,919.00 |
| Strides Pharma Science Limited | STAR | ₹863.60 | ₹79,600,355,810.00 | ₹85,803.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹478.65 | ₹73,282,300,062.00 | ₹136,589.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹708.30 | ₹64,205,475,507.00 | ₹171,833.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹327.45 | ₹64,043,265,649.00 | ₹194,387.00 |
| FDC Limited | FDC | ₹364.30 | ₹59,311,713,601.00 | ₹46,671.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹130.92 | ₹42,486,366,301.00 | ₹619,172.00 |
| Innova Captab Limited | INNOVACAP | ₹668.35 | ₹38,246,281,297.00 | ₹12,022.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹316.30 | ₹34,465,713,320.00 | ₹32,182.00 |
| Suven Life Sciences Limited | SUVEN | ₹149.76 | ₹34,066,506,240.00 | ₹112,567.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹369.70 | ₹33,742,519,000.00 | ₹60,664.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹630.60 | ₹31,983,467,613.00 | ₹129,611.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,914.20 | ₹31,658,982,513.00 | ₹9,690.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹279.30 | ₹28,008,903,926.00 | ₹39,032.00 |
Key Executives
Executive & Whole Time Director
Vibha Gagan Sharma
Gender: Not Specified
Year Born: 1983
Executive & Whole Time Director
Shruti N. Vishal Rao
Gender: female
Year Born: 1985
Chief Financial Officer
Deepak Sawant
Gender: male
Year Born: 1980
MD & Director
Gagan Harsh Sharma
Gender: male
Year Born: 1983
Vice President of Technical Operations
Prashant Churi
Gender: male
Year Born:
Chief Executive Officer
Shibroor Narsimha Kamath
Gender: male
Year Born: 1953
Head of Legal
Shreekrushna Joshi
Gender: male
Year Born:
Associate Vice President
Sourya Das
Gender: male
Year Born:
Compliance Officer, Company Secretary & Nodal Officer
Aditi H. Bhatt
Gender: female
Year Born:
FAQs about Bliss GVS Pharma Limited
Who is the CEO of the company?
The CEO is Shibroor Narsimha Kamath.
What is the current market price of the stock?
The current price is ₹219.02.
What is the 52-week price range?
The range is ₹108.12-243.9.
What is the market capitalization of the company?
The market capitalization is ₹2,316.99 crores.
What is the dividend yield?
The dividend yield is 0.46%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 21.23.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Bliss GVS Pharma Limited (ISIN: INE416D01022) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹2,316.99 crores and an average daily volume of 5,371,498 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹1.